Abstract
Augmentation cystoplasty and urinary diversion are no longer commonplace in the management of patients with neurogenic bladder, but remain an important surgical treatment for those with refractory LUTS who have failed neuromodulation and onabotulinum toxin treatment or who are not candidates for those treatments. Augmentation is an option in patients who can perform intermittent catheterization and is usually performed with ileum or large intestine. Some patients benefit from continent cutaneous catherizable channels. Supravesical urinary diversion may be necessary in more severe cases. Ileovesicostomies are being supplanted by indwelling suprapubic catheters, and when catheters fail conduits may be a better option. When feasible, the diverted bladder should be excised to avoid pyocystis.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
• Biers SB, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJUI. 2011;109:1280–93. An excellent review of the current role for augmentation cystoplasty.
• Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol. 2011;29:51–7. This cost analysis compares onabotulinum toxin with augmentation cystoplasty, considering variables of efficacy duration and complication rates.
Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–40.
Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur Urol. 1998;34:40–2.
Khoury JM, Webster GD. Augmentation cystoplasty. World J Urol. 1990;8:203–4.
• Ivancić V, DeFoor W, Jackson E, et al. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010;184:1768–74. A series of pediatric patients undergoing augmentation mostly had stable or improved renal function, whereas conventional wisdom would suggest they should undergo incontinent diversion.
Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol. 1989;142:505–8.
Rivas DA, Chancellor MB, Huang B, Epple A, Figueroa TE. Comparison of bladder rupture pressure after intestinal bladder augmentation (ileocystoplasty) and myomyotomy (autoaugmentation). Urology. 1996;48:40–6.
Perovic SV, Djordjevic ML, Kekic ZK, Vukadinovic VM. Detrusorectomy with rectus muscle hitch and backing. J Pediatr Surg. 2003;38:1637–41.
Gurocak S, De Grier RP, Feitz W. Bladder augmentation without integration of intact bowel segments: critical review and future perspectives. J Urol. 2007;177:839–44.
Rocha FT, Bruschini H, Figueiredo JA, et al. Use of an inflatable silicone balloon improves the success rate of bladder autoaugmentation at long-term followup. J Urol. 2011;185:2576–81.
Kaibafzadeh AM, Farrokhi-Khajeh-Pasha Y, Ostovaneh MR, Nezami BG, Hojjat A. Teapot ureterocystoplasty and ureteral Mitrofanoff channel for bilateral megaureters: technical points and surgical results of neurogenic bladders. J Urol. 2010;183:1168–74.
Johal NS, Hamid R, Aslam Z, et al. Ureterocystoplasty: long-term functional results. J Urol. 2008;179:2373–5.
Barrett D. Surgery for the neuropathic patient (Committee 20). In: Abrams P, Khoury S, Wein A, editors. Incontinence. London: Health Publication Limited; 1999. p. 813–6.
• Gurung, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012;109:1236–42. One of the largest and longest series of neurologically impaired patients who have undergone ileocystoplasty, demonstrating the long-term success and satisfaction.
Vaida P, Pinter AB, Harangi F, et al. Metabolic findings after colocystoplasty in children. Urology. 2003;62:542–6.
Sarosdy MF. Continent urinary diversion using cutaneous ileocecocystoplasty. Urology. 1992;40:102–6.
• Choi J, Liu J, Boone T, Fletcher S. Ileocecal augmentation cystoplasty: “The Indiana Augment.”. Neurourol Urodyn. 2011;30:1070–70. The largest available series demonstrating the success of ileocecocystoplasty as a combination augmentation and continent catheterizable channel.
Shakeri S, Aminsharifi A, Jahanabadi Z. Application of appendicular-based cecal flap for less invasive augmentation cystoplasty: a novel technique. Urol Int. 2009;83:271–6. The authors present a novel technique for augmentation and catheterizable channel that uses a portion of cecum without requiring bowel anastomosis.
Adams MC, Mitchell ME, Rink RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol. 1988;140:1152–6.
Leonard MP, Dharamsi N, Williot PE. Outcome of gastrocystoplasty in tertiary pediatric urology practice. J Urol. 2000;164:947–50.
• Leslie B, Lorenzo AJ, Moore K, et al. Long-term follow-up and time to event outcome analysis of continent catheterizable channels. J Urol. 2011;185:2298–302. This large and long series of pediatric patients with continent catheterizable channels illustrates the channel-related complication and reoperation rates.
Van der Aa F, Joniau S, De Baets K, De Ridder D. Continent catheterizable vesicostomy in an adult population: success at high costs. Neurourol Urodyn. 2009;28:487–91.
Eisenberg L, Johnson J, Santucci R. Pilot study of the vesicocutaneous continent catheterizable stoma (Mitrofanoff) in adults – high complication rates. Urology. 2012;79:222–6.
Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173:1318–22.
• Hellenthal NJ, Short SS, O’Connor RC, et al. Incontinent ileovesicostomy: long-term outcomes and complications. Neurourol Urodyn. 2009;28:483–6. An excellent series of patients undergoing ileovesicostomy shows a high rate of complications and reoperations, including conversion to ileal conduit.
Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. Fate of the leftover bladder after supravesical urinary diversion for benign disease. J Urol. 2006;176:620–1.
Eigner EB, Freiha FS. The fate of the remaining bladder following supravesical diversion. J Urol. 1990;144:31–3.
Tung GA, Papanicolaou N. Pyocystis with urethral obstruction: percutaneous cystostomy as an alternative to surgery. Can Assoc Radiol J. 1990;41:350–2.
Singh G, Wilkinson JM, Thomas DG. Supravesical diversion for incontinence: a long-term follow-up. Br J Urol. 1997;79:348–53.
Doherty AP, Bellringer J. Stapled vaginal vesicostomy for pyocystis in the defunctioned female bladder. BJU Int. 1999;83:339–40.
Lees JA, Falk RM, Stone WJ, McDougal WS. Pyocystis, pyonephrosis and perinephric abscess in end stage renal disease. J Urol. 1985;134:716–9.
Granados EA, Salvador J, Vicente J, Villavicencio H. Follow-up of the remaining bladder after supravesical urinary diversion. Eur Urol. 1996;29:308–11.
Disclosure
The authors have no potential conflicts of interest relevant to this article to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sajadi, K.P., Goldman, H.B. Bladder Augmentation and Urinary Diversion for Neurogenic LUTS: Current Indications. Curr Urol Rep 13, 389–393 (2012). https://doi.org/10.1007/s11934-012-0271-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11934-012-0271-z